Pharmaceutical company Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Wednesday the receipt of a milestone payment of USD3m for ORMD-0801 under a prior license and investment agreement with Hefei Tianhui Incubator of Technologies Co Ltd (HTIT).
To date, Oramed has received a total of USD33m in payments for ORMD-0801 from HTIT.
China is currently the largest single diabetes population in the world, stated Oramed CEO Nadav Kidron. We are very pleased with the continuing development of our partnership with HTIT in bringing ORMD-0801 to this important market.
In addition, Oramed is seeking to revolutionise the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). It has completed multiple Phase II clinical trials under an Investigational New Drug application with the US Food and Drug Administration.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval